Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Neoplasm, Residual 1Mesothelioma 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lung Neoplasms 1Leukemia, Hairy Cell 1Leukemia 1Epstein-Barr Virus Infections 1Carcinoma, Transitional Cell 1

Interventions

Cyclophosphamide 119fludarabine phosphate 97Cytarabine 86fludarabine 74Methotrexate 70Rituximab 68Busulfan 56Whole-Body Irradiation 48Filgrastim 48Tacrolimus 43Mycophenolic Acid 43Antilymphocyte Serum 40Etoposide 37Peripheral Blood Stem Cell Transplantation 36Granulocyte Colony-Stimulating Factor 35Melphalan 34Vincristine 33Alemtuzumab 33Cyclosporine 32Clofarabine 30Azacitidine 30Dexamethasone 29Imatinib Mesylate 26thymoglobulin 25Doxorubicin 23sargramostim 22Lenalidomide 22Methylprednisolone 20Stem Cell Transplantation 19Daunorubicin 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia × Caves × Clear all
NCT00923013 2025-08-08

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
175 enrolled 16 charts
Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡